Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Open-Label Cross-Over Comparison of Umeclidinium/Vilanterol vs Tiotropium/Olodaterol in Moderate COPD
2016-000585-36Phase 4Completed
- Sponsor
- GSK
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vilanterol and tiotropium + olodaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Trough FEV1. Started May 2016; status: completed.
02
Drugs
vilanteroltiotropium + olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2016-000585-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000585-36.